dlk 1

DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration

URMC-099 是一种具有优异的血脑屏障穿透性的，可口服的混合谱系激酶 3 抑制剂，IC50为14 nM。

GDC-0134是一种dual leucine zipper kinase (DLK)抑制剂，具有脑穿透特性。其通过抑制DLK来预防神经元退化并阻止JNK激活，可能用于治疗肌萎缩侧索硬化症 (ALS)。该药物已在针对ALS患者的I期研究中进行评估。